Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Some diabetes meds might lower risk of dementia, Parkinson's
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
These Diabetes Drugs Could Help Lower Your Risk of Dementia, Parkinson’s
According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
Sodium-glucose cotransporter-2 (
SGLT2
) inhibitors, also known as gliflozins, lower blood sugar by prompting the kidneys to filter sugar out of the bloodstream and excrete it in urine, researchers said. But these drugs might also protect brain health ...
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.
SGLT2 inhibitors tied to lower risk of dementia, Parkinson’s disease, suggests study
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson’s disease, according to a study published in the September 18, 2024, online issue of Neurology®,
Some diabetes medications linked to lower dementia, Parkinson's disease risk
Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By encouraging the kidneys to eliminate sugar from the body through urine, they reduce blood sugar.
GlobalData on MSN
20d
Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis
A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...
Medscape
10d
Do SGLT2 Inhibitors Benefit Everyone With T2D and CKD?
New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Secret Service admits failure
Kentucky judge fatally shot
Secret Service probing post
Body found in SUV
Russia threatens retaliation
$230 million crypto theft
Feds subpoena Schaeffer
Pandas leaving for China
SC 1st execution in 13 years
Hiker injured in bear attack
Whooping cough cases spike
House repeals emission rules
1st rabies outbreak in seals
Hand count approved in GA
FDA approves flu vaccine
Sues pharmacy middlemen
Jurors begin deliberations
144K+ Mavericks recalled
WI high court to decide
Bill to boost security OK'd
Stein's ballot bid rejected
Recalling 449K+ vehicles
Top Hezbollah leader killed?
Baby powder recalled
MS sheriff's office probe
Sesame Place suit verdict
Raises settlement offer
In-person voting begins
Drug price challenge revived
Disney to stop using Slack
Related topics
Parkinson's disease
diabetes
Feedback